<i id='4876E8D45A'><strike id='4876E8D45A'><tt id='4876E8D45A'><pre id='4876E8D45A'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections 
Merck, Daiichi strike cancer drug pact worth up to $22 billion
Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections 
A Theranos scientist 
United colonoscopy coverage change 'may cost lives,' doctors say 
STAT Summit: Meghan O’Rourke on making chronic illness visible 
New air purifier tech could be key to improving indoor air quality 
Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit 
What does generative AI mean for health care? We asked experts 
Johnson & Johnson sues to stop Medicare negotiation 
Alkermes shareholders re 
Cassava Sciences’ Alzheimer’s clinical trials should be halted 
DIEP, the 'gold standard' of breast reconstruction, is under threat 
DeSantis says Trump could've 'come out more forcefully' during Jan. 6 
Duchenne breakthrough therapy leaves behind pioneering families 
